Cas:51240-95-0 2,4,4-trimethylpentan-2-yl 3-(5,5-dimethylhexyl)dioxirane-3-carboxylate manufacturer & supplier

Chemical Name:2,4,4-trimethylpentan-2-yl 3-(5,5-dimethylhexyl)dioxirane-3-carboxylate

CAS.NO:51240-95-0

Synonyms:EINECS 257-077-0;Neodecaneperoxoic acid,1,1,3,3-tetramethylbutyl ester;1,1,3,3-Tetramethylbutyl peroxyneodecanoate

Molecular Formula:C₁₈H₃₄O₄

Molecular Weight:314.46000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:333.8ºC at 760 mmHg

Density:0.971 g/cm3

Index of Refraction:1.456

PSA:51.36000

Exact Mass:314.24600

LogP:5.00900

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like EINECS 257-077-0 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,1,3,3-Tetramethylbutyl peroxyneodecanoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Neodecaneperoxoic acid,1,1,3,3-tetramethylbutyl ester Use and application,1,1,3,3-Tetramethylbutyl peroxyneodecanoate technical grade,usp/ep/jp grade.

Related News: As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company��s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations. 2,4,4-trimethylpentan-2-yl 3-(5,5-dimethylhexyl)dioxirane-3-carboxylate manufacturer Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 2,4,4-trimethylpentan-2-yl 3-(5,5-dimethylhexyl)dioxirane-3-carboxylate supplier Pre-approval Access Programs (also known as expanded access, early access, compassionate use, named patient supply) are regulatory-compliant processes permitting experimental agents in development to be made available upon the request of a physician or a patient for appropriate patients for whom no alternative treatment option exists in their country. 2,4,4-trimethylpentan-2-yl 3-(5,5-dimethylhexyl)dioxirane-3-carboxylate vendor Especially tumor drugs with selective targeting characteristics. At present, about 80% of small drug (high-efficiency drug) APIs worldwide are patented drugs. 2,4,4-trimethylpentan-2-yl 3-(5,5-dimethylhexyl)dioxirane-3-carboxylate factory She said she revealed her diagnosis in the interest of transparency but in truth really mostly as a shoutout to early diagnosis,” and wanted to “urge women to educate themselves on this disease; to get all the regular screenings and scans that you can; to always listen to your bodies; and of course to ensure that your legitimate medical concerns are not dismissed or diminished.